RYTM · XBRL financial data

Rhythm Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RYTM's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	3	24	77	130	190
Cost of goods and services sold	—	1	2	9	13	19
Research and development	90	104	109	135	238	167
Selling, general and administrative	46	68	92	118	144	195
Total operating expenses	137	—	—	—	—	—
Operating income (loss)	(137)	(170)	(179)	(184)	(266)	(192)
Interest income	3	0	—	—	—	—
Interest expense	—	—	5	14	21	21
Other income (expense)	—	100	(1)	0	2	1
Income tax expense (benefit)	—	—	—	1	0	0
Net income (loss)	(134)	(70)	(181)	(185)	(261)	(197)
Earnings per share, basic USD per share	(3.04)	(1.40)	(3.47)	(3.20)	(4.34)	(3.11)
Earnings per share, diluted USD per share	(3.04)	(1.40)	(3.47)	(3.20)	(4.34)	(3.11)
Weighted average shares, basic millions of shares	44	50	52	58	61	65
Weighted average shares, diluted millions of shares	44	50	52	58	61	65

Fiscal years (RYTM's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	101	59	128	60	89	54
Short-term investments	72	236	206	216	231	335
Accounts receivable	—	1	6	15	19	26
Inventory	—	0	3	9	19	26
Prepaid and other current assets	9	13	12	9	16	26
Total current assets	182	308	354	308	374	467
Property and equipment, net	3	3	2	1	1	1
Right-of-use asset	2	2	1	1	3	3
Total assets	187	330	382	333	392	480
Accounts payable	5	6	5	5	12	14
Accrued liabilities	13	30	33	48	63	84
Current portion of long-term debt	—	—	—	—	2	7
Total current liabilities	18	43	40	55	116	106
Long-term debt	—	—	—	106	108	101
Lease liability, non-current	—	2	1	0	4	3
Total liabilities	21	45	118	163	228	210
Accumulated deficit	(459)	(529)	(710)	(895)	(1,155)	(1,352)
Total stockholders' equity	167	284	264	170	22	139
Total liabilities and equity	187	330	382	333	392	480
Common shares outstanding (cover page) millions of shares	50	50	57	60	63	68

Fiscal years (RYTM's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(134)	(70)	(181)	(185)	(261)	(197)
Stock-based compensation	17	21	20	33	40	67
Depreciation and amortization	1	1	1	1	1	1
Net cash from operating activities	(122)	(146)	(173)	(136)	(114)	(116)
Purchases of property and equipment	0	0	0	0	0	1
Net cash from investing activities	159	(62)	28	(6)	(48)	(137)
Proceeds from issuing common stock	—	162	131	49	39	34
Proceeds from long-term debt	—	—	72	24	0	0
Repayments of long-term debt	—	—	—	7	13	20
Net cash from financing activities	2	166	214	74	191	218
Net change in cash	39	(42)	68	(68)	29	(35)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Rhythm Pharmaceuticals	40	92	(3.1)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026
Vaxcyte	183	not reported	(232)*	148.8M	6.4 quarters	Q2 FY26 10-QJun 30, 2026
Dynavax Technologies	160	95	34*	117.4M	—	Q3 FY25 10-QSep 30, 2025
PERRIGO	400	1,023	83*	138.8M	—	Q2 FY26 10-QJun 27, 2026
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026
Adma Biologics	136	124	30*	224.0M	—	Q2 FY26 10-QJun 30, 2026
Ultragenyx Pharmaceutical	125	214	(97)*	98.6M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Avidity Biosciences	383	0.9*	(170)*	155.1M	2.3 quarters	Q4 FY25 10-KDec 31, 2025
Lantheus Holdings	593	388	92*	65.3M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.